30 closest matches · ranked by relevance
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
Primary: Progression Free Survival (PFS) — 6.86; 13.00 weeks — p=0.0022
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
BRAF or NRAS Mutant Metastatic Melanoma
Primary: Percentage of Participants With Objective Response (OR) — 4.9; 14.5; 12.0 percentage of participants
Mucosal Lentiginous Melanoma · Acral Melanoma · Melanoma
Primary: 4-month Progression-Free Survival Rate — 0.27; 0.125 proportion of patients
Locally Advanced or Metastatic NRAS Mutant Melanoma
Primary: Number of Dose Limiting Toxicities (Phase Ib) — 2; 0; 1; 3 occurrence
Recurrent Melanoma · Stage IIIB Melanoma · Stage IIIC Melanoma
Primary: Overall Response Rate in "High Affinity" Group — 0.5 Proportion of participants
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
KRAS NP_004976.2:p.G12R · Stage III Pancreatic Cancer AJCC v6 and v7 · Stage IV Pancreatic Cancer AJCC v6 and v7
Primary: Proportion of Participants With an Objective Response (Partial Response + Complete Response) — 0; 0; 0; 0 Proportion of participants
KRAS Gene Mutation · Metastatic Non-Squamous Non-Small Cell Lung Carcinoma · Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
Primary: Incidence of Dose-limiting Toxicity (DLT) of Pembrolizumab and Trametinib Per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version 4.0…
Metastatic Melanoma
Primary: Progression-free Survival — 4 months
Lung Cancer, Non-Small Cell
Primary: Progression-Free Survival (PFS) as Assessed by the Investigator (INV) — 11.7; 11.4 Weeks — p=0.5197
Melanoma
Primary: Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT) — NA; 36.9; 23.1; 15.4…
Melanoma
Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…
Melanoma
Primary: Overall Response Rate (ORR) — 11; 3 Participants
Metastatic Melanoma · Brain Metastases
Primary: Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset — 34; 13; 1; 20 Participants
Melanoma · Unresectable (Stage III) Melanoma · Metastatic (Stage IV) Melanoma
Primary: Measure of Efficacy of the Phase 2 Dose of RTA 408 in Combination With Nivolumab Using Overall Response Rate (ORR; Complete Plus Partial Responses) According to RECIST…
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Melanoma
Primary: Dose Limiting Toxicity (DLT) [Phase I] — 1 Participants
Melanoma
Primary: Number of Participants With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator for Participants Who Had…
Colorectal Cancer
Primary: OS in Participants With Left-sided Tumors — 37.85; 34.30 Months
Melanoma
Primary: Part 1: Progression Free Survival (PFS) by BIRC in Combo 450 Group as Compared to Vemurafenib Group — 14.9; 7.3 Months
Melanoma
Primary: Number of Participants With Dose Limiting Toxicities (DLT) [Phase I] — 1 Participants
Malignant Melanoma
Primary: Plasma RO5185426 Trough Concentrations on Days 15,16, and 17 — 61.1; 67.7; 61.5 micrograms per milliliter
Cancer
Primary: Progression-free Survival (PFS) as Assessed by the Investigator — 6.9; 2.7 Months — p=<0.0001
Melanoma (Skin)
Primary: Objective Response Rate Among KIT-positive Patients — 0.182 proportion of participants
MSS · RAS-mutant Colorectal Cancer
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1; 2 Participants
Malignant Melanoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) During DES in Combination Cohorts — 0; 0; 1; 0 participants
Malignant Melanoma
Primary: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events…
Recurrent Melanoma · Stage IIIA Melanoma · Stage IIIB Melanoma
Primary: Best Overall Response Rate (BORR) — 2; 17; 1 Participants